---
title: "Dauch Corporation: Buy Rating Reaffirmed as Merger Synergies Strengthen Fundamentals; $17 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295419566.md"
description: "BWS Financial analyst Hamed Khorsand reaffirmed a Buy rating on Dauch Corporation with a $17 price target. The decision is based on strong fundamentals following the Dowlais merger, including resilient Q2 revenue of $2.96 billion and expanding gross margins. Updated guidance addresses leverage concerns, while solid liquidity and early synergy realization support an attractive risk-reward profile."
datetime: "2026-08-10T13:55:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295419566.md)
  - [en](https://longbridge.com/en/news/295419566.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295419566.md)
generator: "portal-rs"
---

# Dauch Corporation: Buy Rating Reaffirmed as Merger Synergies Strengthen Fundamentals; $17 Price Target Maintained

Dauch Corporation, the Consumer Cyclical sector company, was revisited by a Wall Street analyst today. Analyst Hamed Khorsand from BWS Financial maintained a Buy rating on the stock and has a $17.00 price target.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Hamed Khorsand has given his Buy rating due to a combination of factors tied to Dauch Corporation’s improving fundamentals and execution on its merger strategy. He notes that the second quarter, the first full period following the Dowlais merger, already shows initial merger benefits, with stronger-than-expected revenue of $2.96 billion highlighting resilient demand and expanding gross margins.

Khorsand also emphasizes that updated full-year guidance directly addresses prior investor worries around leverage and the company’s ability to generate free cash flow. With a solid liquidity position, a clear path toward deleveraging, and early synergy realization, he believes the risk-reward profile remains attractive, supporting a Buy rating while maintaining a $17 price target.

### Related Stocks

- [DCH.US](https://longbridge.com/en/quote/DCH.US.md)

## Related News & Research

- [Dauch Corporation: Buy Rating Reaffirmed as Guidance Raised and $17 Price Target Maintained Post-Dowlais Merger](https://longbridge.com/en/news/286131547.md)
- [Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged](https://longbridge.com/en/news/296135927.md)
- [Analyst Maintains Buy on Surrozen, Reiterates $46 Price Target on Novel Wnt Pathway Strategy in Retinal Disease](https://longbridge.com/en/news/296138314.md)
- [Canaccord Genuity Reaffirms Their Buy Rating on Labyrinth Resources Limited (GG8)](https://longbridge.com/en/news/296216069.md)
- [Prime Medicine Maintained at Buy with Unchanged $6 Price Target on Emerging Program Clarity and 2027 Catalysts](https://longbridge.com/en/news/296139179.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**